VANCOUVER, BC, Nov. 4, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased to provide an operational progress update on the strategic initiatives of its operating segments – MINDCURE Research and MINDCURE Technology. MINDCURE Research: Synthetic Ibogaine…


Previous articleThe Missing Mushroom: Psychedelic Science and the Future of Psilocybin
Next articleComplete Results from Red Light Oregon Market Research in Oregon Show Microdosing Services Market Size per Annum Estimated at a Billion USD